PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21455800-9 2012 Both docetaxel and sunitinib malate had no effect on each other in inhibiting ERK1/2 phosphorylation in sequential treatments, while docetaxel eliminated inhibitory activity of sunitinib malate on ERK1/2 phosphorylation in concurrent treatment. Sunitinib 177-193 mitogen-activated protein kinase 3 Homo sapiens 197-203 22442268-4 2012 RESULTS: Sunitinib was found to selectively inhibit cell proliferation, induce cell accumulation in the G0-G1 phase, and inhibit the phosphorylation of ERK1/2 in both KRAS/BRAF wild-type thyroid cancer cells and in tumor cells harboring the RET/PTC rearrangement, whereas it was completely ineffective in KRAS- or BRAF-mutated thyroid carcinoma cells. Sunitinib 9-18 mitogen-activated protein kinase 3 Homo sapiens 152-158 22442268-6 2012 Of note, the constitutive activation of RAS/RAF/ERK signaling in KRAS/BRAF wild-type cells by transfection of the R12 HRAS or V600E BRAF mutants or stimulation with epithelial growth factor resulted in the loss of responsiveness to sunitinib, whereas pharmacological inhibition of MAPK kinase activity resulted in the resensitization of KRAS- or BRAF-mutated cells to the multikinase inhibitor. Sunitinib 232-241 mitogen-activated protein kinase 3 Homo sapiens 281-285 22344606-0 2012 Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Sunitinib 0-9 mitogen-activated protein kinase 3 Homo sapiens 118-124 22344606-5 2012 In the present study, the antiproliferative effects of sunitinib were clearly demonstrated in KK47, KK47/DDP20 and KK47/ADR cell lines in vitro due to the suppression of ERK1/2 phosphorylation. Sunitinib 67-76 mitogen-activated protein kinase 3 Homo sapiens 194-200 20629553-9 2010 Western blot analysis of the p38, MEK/ERK, and SAPK/JNK mitogen-activated protein kinase signal transduction pathways showed that sunitinib blocked ERK 1/2 and JNK phosphorylation in the cytoplasm. Sunitinib 130-139 mitogen-activated protein kinase 3 Homo sapiens 148-155 21693010-8 2011 RESULTS: First, in human LECs, sunitinib blocked both VEGFR-2 and VEGFR-3 phosphorylation induced by VEGF-C or VEGF-D, and abrogated the activation of the downstream molecules extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt. Sunitinib 31-40 mitogen-activated protein kinase 3 Homo sapiens 219-225 33135264-9 2021 Thus, sunitinib reduces the expression of KRT6A and SERPINB1 by inhibiting the ERK1/2 and p38 MAPK signaling pathways in the skin model. Sunitinib 6-15 mitogen-activated protein kinase 3 Homo sapiens 79-85 33887553-9 2021 In combination, sunitinib was able to overcome potential crizotinib-induced resistance through downregulation of ERK 1/2 activity and PDGFRss receptor expression; consequently, tumor growth was significantly decreased both in vitro and in vivo. Sunitinib 16-25 mitogen-activated protein kinase 3 Homo sapiens 113-120 33135264-6 2021 In PSVK1 cells, but not in normal human epidermal keratinocyte cells, both of which are human normal keratinocyte cell lines, sunitinib decreased the expression of KRT6A with a concomitant decrease in levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated p38 mitogen-activated protein kinase (MAPK). Sunitinib 126-135 mitogen-activated protein kinase 3 Homo sapiens 266-273 33135264-8 2021 Sunitinib-induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase-3beta by enhancing ERK1/2 and p38 MAPK phosphorylation. Sunitinib 0-9 mitogen-activated protein kinase 3 Homo sapiens 127-133 30821250-8 2019 Analysis of post-receptor pathways controlling proliferation and migration of HUVECs showed suppression of phosphorylated PI3K/Akt and ERK1/2 after exposure to sunitinib but not to 3PO in 10 microM concentration. Sunitinib 160-169 mitogen-activated protein kinase 3 Homo sapiens 135-141 25893276-8 2015 RESULTS: Sunitinib strongly reduced proliferation of PC-3 and DU-145 cells in a dose dependent manner, and decreased levels of p-Akt, p-Erk1/2, and Id-1, compared to untreated cells. Sunitinib 9-18 mitogen-activated protein kinase 3 Homo sapiens 136-142 27990160-13 2016 Sunitinib inhibited phospho-ERK1/2 and phospho-mTOR. Sunitinib 0-9 mitogen-activated protein kinase 3 Homo sapiens 28-34 30200486-8 2018 In contrast, MAPK/ERK kinases (MEK) 1/2 and ERK1/2 kinases remained constitutively phosphorylated after treatment with sunitinib and other relevant protein kinase inhibitors. Sunitinib 119-128 mitogen-activated protein kinase 3 Homo sapiens 44-50 28413468-6 2017 In addition, sunitinib activated ERK1/2 and inhibited mTOR/p70S6K signaling. Sunitinib 13-22 mitogen-activated protein kinase 3 Homo sapiens 33-39 28413468-7 2017 Sunitinib-induced autophagy was notably reversed by ERK1/2 kinase inhibitor, U0126. Sunitinib 0-9 mitogen-activated protein kinase 3 Homo sapiens 52-58 23812726-7 2013 The inhibition of kinase activation using multi-targeted kinase inhibitors, sorafenib and sunitinib led to significant cell growth inhibition and apoptosis induction via suppression of Erk1/2 and Akt activation, whereas drugs with specificity to a single kinase showed less potency. Sunitinib 90-99 mitogen-activated protein kinase 3 Homo sapiens 185-191 23969186-0 2013 Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. Sunitinib 47-56 mitogen-activated protein kinase 3 Homo sapiens 134-140 23969186-10 2013 Phospho-epidermal growth factor receptor, ERK1/2, and Akt phosphorylation was significantly inhibited by sunitinib treatment in endothelial and cancer cells, and cyclin-D1 mRNA and protein expression was inhibited. Sunitinib 105-114 mitogen-activated protein kinase 3 Homo sapiens 42-48 23969186-12 2013 CONCLUSIONS: Sunitinib is active in vitro and in vivo against activated endothelial and ATC cells via the inhibition of Akt and ERK1/2 phosphorylation and through the down-regulation of cyclin-D1. Sunitinib 13-22 mitogen-activated protein kinase 3 Homo sapiens 128-134